Empiric treatment of diarrhea in patient with HIV infection: a case report

Lisa A. Susanto*, I. Made Bayu S. Dana, Ketut Suryana

ABSTRACT

Diarrhea is common opportunistic infection in patient with Human immunodeficiency virus (HIV) infection. Diarrhea in patient with HIV infection that contributes the negatively to quality of life. The etiology of diarrhea in patient with HIV infection is multifactorial include infectious, non-infectious, ART-association diarrhea. In addition, this diarrhea can be associated with empiric therapy. This article a 31 years old male patient with 3 days fatigue and diarrhea. Physical examination dry mucous membranes, abdominal pain especially in the upper abdomen and increase small bowel peristalsis. Stool examination test doesn’t have blood, parasites, and fungi. Stool cultures for Salmonella, Shigella, Campylobacter organisms no presence. The treatment metronidazole oral 500 mg every 8 hours was again performed. Metronidazole is available for the management of diarrhea in patient with HIV that can’t be treated with other antibiotics.

Keywords: Diarrhea, HIV, Metronidazole

INTRODUCTION

Infection with human immunodeficiency virus (HIV) imposes monumental suffering on affected individual and in the developing world in particular it places a great burden on the medical system. For Indonesia as a developing country with the population of 240 million spread across 514 cities and districts, faces specific challenge in its response to HIV. One of the most health problems among HIV destroys the immune system and renders patients susceptible to opportunistic infection.1,2

Diarrhea is described as three or more loose or watery stools with the contain of water more than 200 gram or 200 ml/24 hours. The classification of diarrhea is acute diarrheal are due to infectious etiology and chronic diarrhea is commonly categorized in three groups; watery (secretory and osmotic), fatty (malabsorption), or inflammation. Patient are usually diagnosed with chronic diarrhea when this pattern is abnormal passage of three or more loose or liquid stools per day for more than 4 weeks and/or daily stool weight greater than 200g/day.3 Chronic diarrhea is one such very common clinical condition in AIDS-defining, according to World Health Organization (WHO) criteria.1

The etiology of diarrhea in patients with HIV is opportunistic infectious agents that cause protozoa, fungi, viruses and bacteria; and noninfectious diarrhea includes ART-associated diarrhea and gastrointestinal damage related to HIV infection (enteropathy).4 In addition, infectious diarrhea can be caused by pathogens that are unique to the HIV population depend on standard of living among developed versus developing countries and differences in availability of care for patients with HIV, the incidence and type of various diarrhea-associated infections in immunocompromised patients may vary substantially by region.5,7

In other hand the site of origin of the diarrhea small bowel (“enteritis”) or colon (“colitis”). Enteritis is classically manifested as large volume (often > 2L/d) watery stools,
often associated with dehydration, electrolyte disturbances, malabsorption and weight loss. In contrast colitis is characterized by frequent, small volume stools, which may contain mucus, pus and/or blood, tenesmus, frequency, urgency, dyschezia and proctalgia.8

With the previous background, this study discuss the empiric therapy in HIV/AIDS cases with diarrhea. This study was to understand the microbial etiologies of diarrhea, specific therapy for this patient.

**CASE REPORT**

A 31 years old male patient came to the emergency department with three days fatigue and diarrhea. Diarrhea with watery stool, frequency of defection of four times in a day, no bloody, mucoid, fatty, pus stools accompanied by nausea and vomiting, lack of appetite and drink. Patients also complain of abdominal pain or crampy in all part of abdomen, bloating, flatulence dan fever. Patients had history about HIV and toxoplasmosis with the routine treatment use ARV (tenofovir + lamivudine + efavirenz) and in one month patient doesn’t consume of toxoplasmosis drug.

Physical examination showed a blood pressure of 120/80 mmHg, heart rate of 88 beats per minute, respiratory rate of 18 times per minute, body temperature of 37.8 °C, dry mucous membranes. The abdominal pain especially in the upper abdomen and increase small bowel peristalsis.

The laboratory examination results were: white blood cells 3.23 x 103/ μL; Hemoglobin level 8.4 g/dl; hematocrit 23.4%; platelet count 179 x 103/ μL; SGPT 171 U/L; SGOT 171 U/L; BUN 292 mg/dl; SC 9.3 mg/dl; Na 121 mmol/L; K 3.3 mmol/L; Cl 98 mmol/L. Stool examination (macroscopic and microscopic) doesn’t have blood, parasites, and fungi. Stool culture for Salmonella, Shigella, Campylobacter, Staphylococcus, E. coli organisms no presence. No abnormalities were found on chest x-ray.

The diagnosis of HIV AIDS, toxoplasmosis and chronic diarrhea was made at the end evaluation. In the hospitalization, patient was treated with esomeprazole injection 40 mg BID, cefoperazone injection 1 gram BID, attapulgite 2 tablets TID, azitromisin tablet 500 mg, metronidazole tablet 500 mg TID.

**DISCUSSION**

Diarrhea is described as three or more loose or watery stools with the contain of water more than 200 gram or 200 ml/24 hours.5 Diarrhea disease is a common complication of HIV infection among adults seen in more than 50% of all patients with AIDS. HIV has an impact on intestinal infection at all stages, but the effects of HIV on the mucosal immune system are most apparent in acute infection period. Data from patients with HIV show that within weeks of infection, the mucosal lamina propria CD4+ lymphocytes are depleted. This depletion occurs well before any decrease in CD4+ T cells is seen in the periphery and likely reflects the greater expression of the CC chemokine receptor type 5 (CCR5), which functions as the primary coreceptor for the majority of infective HIV strains, on mucusal CD4+ cells.9 The expression of the chemokine receptor on these cells supports the entry of the virus, but their state of physiologic activation is responsible for enhanced HIV replication in the mucosal compartment and subsequent mucosal CD4+ T cell depletion. HIV persist within Gut-associated lymphoid tissue (GALT) lymphocytes, even after repletion of CD4+ T cells in the periphery.10 The etiology of diarrhea in HIV-infected patients is multifactorial such as infectious and noninfectious.

The infectious causes of diarrhea in AIDS are bacteria and mycobacteria, parasites, virus and fungi and the most important etiologic agents will be briefly discussed individually focusing on geographic differences in prevalence. In the world population, the most common causes of diarrhea in HIV-infected patients are enteric bacteria including Shigella flexneri, Salmonella enteritidis and Campylobacter jejuni. In contrast to the normal host, these bacteria have been identified in stool from patients with chronic diarrhea.11-13 Clostridium difficile is a prevalent pathogen in developed countries, whereas tuberculosis is a common complication of AIDS in developing countries.14,15 Cryptosporidia is the most frequently identified parasitic cause of diarrhea throughout the world.11-13

In other hand the etiology agents of origin diarrhea in HIV infection in the intestine. Small intestine (“enteritis”): Cryptosporidia, Microsporidia, Isospora belli, Mycobacterium avium complex, Salmonella species, Campylobacter species, Giardia lamblia. Large intestine (“colitis”): Cytomegalovirus, Cryptosporidia, Mycobacterium avium complex, Shigella sonnei, Clostridium difficile, Campylobacter jejuni, Histoplasma capsulatum, Adenovirus, Herpessimplex, Pneumocystis carinii.8,16

HIV enteropathy is a non-infection form of diarrhea in patients with HIV. It occurs in 50% of patients and is characterized by rather watery diarrhea and worsen with the consumption of food but improves with defecation because the mechanism are unclear.17 Several studies have established crypt epithelial proliferation in response to HIV infection, malabsorption, decreased transepithelial electrical resistance, decreased sodium-dependent glucose absorption, and increased intercellular permeability in HIV-infected cells.18-20 On the other hand diarrhea has also been described as a side effect of ARV. Rufo and colleagues demonstrated that protease inhibitors in general and nelfinavir in particular potentiate signaling through muscarinic and calcium-dependent receptors of intestinal cells, resulting in increased chloride secretion into the lumen. This study also showed that sodium and chloride concentrations in stool samples from patients with HIV
taking nelfinavir were elevated, consistent with secretory diarrhea.21,22

The basic algorithm for the diagnosis and evaluation of diarrhea in patients with HIV to the examination of diarrhea in the immunocompetent host and starts with a through medical history, a careful review of medications, travel history, contact with ill individuals, recent ingestions, family history, surgical history, and social history is in evaluating acute and chronic diarrhea in the patient infected with HIV. Physical examination and medical history of a patient with HIV such as basic vital signs, orthostatic vital sign, biternostal wasting, weight changes, skin turgor, mucosal dehydration, gastrointestinal examination is to evaluate the severity and causes of diarrhea. Laborator test should include complete blood count with cell differential, blood cultures, HIV viral load, and CD4+ T cell count to measure the level of immune suppression. Fecal examination to evaluation causes diarrhea from bacteria, parasites, fungi. If non pathogen is identified, workup needed with an endoscopic examination.23

The case at hand had diagnosis HIV AIDS and chronic diarrhea, this case can be diagnosed as chronic diarrhea because diarrhea during three days and watery stool, frequency of defecation of four times in a day. Etiology diarrhea in this case can’t not defined specific because in day II evaluation with fecal examination and cultures examination doesn’t have result use empiric therapy and in day V fecal and cultures examination no presence. Anamnesa and physical examination diarrhea with watery stool, no mucoid, bloody, fatty, pus, fever and have crampy in all part of abdomen etiology agents origin diarrhea in small intestine (“enteritis”).

HIV patients with diarrhea therapy consider to treat HIV infection and diarrhea. Treatment of diarrhea in patients with HIV is essential connected with a state of decreased immunity, opportunistic infection. General therapy for treatment of noninfectious diarrhea in patients with HIV are primarily supportive. Hydration via intravenous and oral routes, repletion of electrolytes and treating the underlying cause, if possible, are important therapies for any patient with diarrhea.24 Antidiarrheal medications used in noninfectious diarrhea can be divided into several classes: adsorbents, antimotility, antisercretry agents.24–33 Adsorbent drugs bind bacterial toxins, fluids, and other compound in the intestines to improve stool consistency include attalpugite, bismuth subsalicylate, kaolin, pectin. Antimotility agents include loperamide, diphenoxylate/atropine, tincture of opium.27 In addition to supportive, antimicrobials are widely used to treat infectious diarrhea in patient with HIV AIDS depend on etiology bacterial infection for example: management of Campylobacter infection is based on ciprofloxacin recommended for 14 days, mycobacterium avium complex with oral 500 mg clarithromycin every 12 hours, clostridium difficile with oral 500 mg metronidazole every 8 hours for 10 to 14 days or oral of 125-250 mg vancomycin every 6 hours for 10 to 14 days.34–36 Etiology of parasitic infection therapeutic option in Isospora belli are trimetropim/sulfamethoxazole (160 mg/800mg) every 6 hours for 10 days or 500 mg of ciprofloxacin every 12 hours for 7 days.37

In this case the patient was first treated for diarrhea with cefoperazone injection 1 g BID and azitromisin oral 500 mg every 24 hours without clinical improvement or reduction of diarrhea until fecal and cultures examination no presence. The patient was treated empiric therapy of metronidazole oral 500 mg every 8 hours, diarrhea was stopped. The second treatment with metronidazole was more continuous in 7 days and efficient. Metronidazole is drug treatment of broad range of infection of anaerobic bacteria, protozoa infection.38

CONCLUSION

Diarrhea is a common opportunistic infection in HIV that has substantial clinical ramification. The major cause of diarrhea in this patient with HIV is infectious agent but can other cause such as noninfectious and use ARV therapy. Medications use for infectious agent include adsorbent drug and antibiotic therapy which has been shown reduce diarrhea patient with HIV.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES

1. Elfstrand L, Florén CH. Management of chronic diarrhea in HIV-infected patients: current treatment options, challenges and future directions. HIV/AIDS - Research and Palliative Care. 2010;2:219-24.
2. Miskin JP, Kemiskinan G, Kemiskinan IK, Kemiskinan IK, Provisini M. Statistics Indonesia. (Number and Percentage of Poor people., the Poverty Line, Poverty Gap Index (P1), and Poverty Severity Index (P2). Jakarta: Badan Pusat Statistik. 2013. Available from: https://www.bps.go.id/linkTabelStatis/view/id/1489. Last accessed on 01 November, 2020.
3. Simadibrata M, Akut DD. In: Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, eds. Buku ajar ilmu penyakit dalam. 6 th ed. Jakarta: Interna publishing. 2014;1899.
4. Dikman AE, Schonfeld E, Srisarajivakul NC, Poles MA. Human immunodeficiency virus-associated diarrhea: still an issue in the era of antiretroviral therapy. Nature public health emergency collection. 2015;60(8):2236-24.
5. Rossit AR, Gonçalves AC, Franco C, Machado RL. Etiological agents of diarrhea in patients infected by the human immunodeficiency virus-1: a review. Rev Inst Med Trop Sao Paulo. 2009;51:59-65.
6. Krones E, Hogenauer C. Diarrhea in the immunocompromised patient. Gastroenterol Clin North Am. 2012;41:677-701.

7. Sanchez TH, Brooks JT, Sullivan PS. Bacterial diarrhea in persons with HIV infection, United States, 1992–2002. Clin Infect Dis. 2005;41:1621-627.

8. Wilcox CM, Schwartz DA, Cotsonis G, Thompson SE. Chronic unexplained diarrhea in human immunodeficiency virus infection: determination of the best diagnostic approach. Gastroenterol. 1996;110:30-37.

9. Anton PA, Elliott J, Poles MA. Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS. 2000;14:1761-765.

10. Chun TW, Nickle DC, Justement JS. Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis. 2008;197:714-20.

11. Blanshard C, Francis N, Gazzard BG. Investigation of chronic diarrhea in acquired immunodeficiency syndrome. A prospective study of 135 patients. Gut. 1996;39:824-32.

12. Weber R, Ledergerber B, Zbinden R, Altwegg M, Pfyffer GE, Spycher MA et al. Enteric infections and diarrhea in human immunodeficiency virus-infected persons: prospective community-based cohort study. Swiss HIV Cohort Study. Arch Intern Med. 1999;159:1473-480.

13. Cotte L, Rabodonirina M, Piens MA, Perreard M, Mojon M, Trepo C. Prevalence of intestinal protozoans in French patients infected with HIV. J Acquir Immune Defic Syndr. 1993;6:1024-029.

14. Karp CL, Neva FA. Tropical infectious diseases in human immunodeficiency virus-infected patients. Clin Infect Dis. 1999;28:947-63.

15. Lanjewar DN, Anand BS, Genta R, Maheshwari MB, Ansari MA, Hira SK et al. Major differences in the spectrum of gastrointestinal infections associated with AIDS in India versus the west: an autopsy study. Clin Infect Dis. 1996;23:482-85.

16. Scott GB. Management of acute illness in HIV-infected children. In: HIV/AIDS Primary Care Guide. Editors: Lawrence M, Tierney. Education and Training University of Florida, Florida. 2002:283-89.

17. Cello JP, Day LW. Idiopathic AIDS enteropathy and treatment of gastrointestinal opportunistic pathogens. Gastroenterology. 2009;136(6):1952-65.

18. Batman PA, Miller AR, Forster SM, Harris JR, Pinching AJ, Griffin GE. Jejunal enteropathy associated with human immunodeficiency virus infection: quantitative histology. J Clin Pathol. 1989;42:275-281.

19. Batman PA, Kotler DP, Kapembwa MS. HIV enteropathy: crypt stem and transit cell hyperproliferation induces villous atrophy in HIV/Microsporidia-infected jejunal mucosa. AIDS. 2007;21:433-39.

20. Maressa M, Mahfoud R, Garmy N, Kotler DP, Fantini J, Clayton F. The virotoxin model of HIV-1 enteropathy: involvement of GPR15/Bob and galactosylceramide in the cytopathic effects induced by HIV-1 gp120 in the HT-29-D4 intestinal cell line. J Biomed Sci. 2003;10:156-66.

21. Rufo PA, Lin PW, Andrade A. Diarrhea-associated HIV-1 APIs potentiate mucinasic activation of Cl-secretion by T84 cells via prolongation of cytosolic Ca2+ signaling. Am J Physiol Cell Physiol. 2004;286:C998-1008.

22. Bode H, Lenzner L, Kraemer OH. The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apoptosis and decrease barrier function in human intestinal epithelial cells. Antivir Ther. 2005;10:645-55.

23. MacArthur RD, DuPont HL. Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era. Clin Infect Dis. 2012;55:860-67.

24. Morpeth SC, Thielman NM. Diarrhea in patients with AIDS. Curr Treat Options Gastroenterol. 2006;9:23-37.

25. MacArthur RD. Clinical Focus: Evolving Options for Managing Noninfectious Diarrhea in HIV-Infected Patients. Clinical Care Options® HIV. 2013. http://www.clinicaloptions.com/HIV/Treatment%20Updates/Noninfectious%20Diarrhea/CCO%20Slideset/Sldeset.aspx. Last accessed on 01 November, 2020.

26. Morpeth SC, Thielman NM. Diarrhea in patients with AIDS. Curr Treat Options Gastroenterol. 2006;9:23-37.

27. Nwachukwu CE, Okebe JU. Antimotility agents for chronic diarrhea in people with HIV/AIDS. Cochrane Database Syst Rev. 2008;8:CD005644.

28. Sherman DS, Fish DN. Management of protease inhibitor-associated diarrhea. Clin Infect Dis. 2000;30:908-14.

29. Imodium A-D, and Imodium multi-symptom relief (loperamide and loperamide-simethicone) [package insert]. Fort Washington, PA: McNeil Consumer Healthcare. 2005.

30. Cottreau J, Tucker A, Crutchley R, Garey KW. Crofelemer for the treatment of secretory diarrhea. Expert Rev Gastroenterol Hepatol. 2012;6:17-23.

31. Matheson AJ, Noble S. Racedoctril. Drugs. 2000;59:829-35.

32. MacArthur RD, Hawkins TN, Brown SJ. Efficacy and safety of crofelemer for noninfectious diarrhea in HIV-seropositive individuals (ADVENT trial): a randomized, double-blind, placebo-controlled, two-stage study. HIV Clin Trials. 2013;14:261-73.

33. Golden P, Mathis A, Chu H. Population pharmacokinetic (PK) analysis demonstrates no drug-drug interactions (DDI) between crofelemer, a novel treatment for noninfectious diarrhea in HIV+ individuals, and antiretroviral therapy (ART).
Presented at: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 2013.

34. Wilcox CM. Gastrointestinal consequences of infection with human immunodeficiency virus. In: Gastrointestinal and liver disease. Feldman M, Friedman LS, Brandt LJ (editors). Elsevier Saunders. 2010;526-30.

35. Gordon SN, Cervasi B, Odorizzi P. Disruption of intestinal CD4 T cell homeostasis is a key marker of systemic CD4 T cell activation in HIV infected individuals. J Immunol.

36. Deshpande A, Pasupuleti V, Rolston DD. Diagnostic accuracy of real-time polymerase chain reaction in detection of Clostridium difficile in the stool samples of patients with suspected Clostridium difficile infection: a meta-analysis. Clin Infect Dis. 2011;53(7):e81-90.

37. Krones E, Högenauer Ch. Diarrhea in the immunocompromised patient. Gastroenterol Clin North Am. 2012;41(3):677-701.

38. Pankuch GA, Jacobs MR, Appelbaum PC. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and ceftoxitin. Antimicrob Agents Chemother. 1993;37(8):1649-54.

Cite this article as: Susanto LA, Dana IMB, Suryana K. Empiric treatment of diarrhea in patient with HIV infection: a case report. Int J Adv Med 2021;8:286-90.